Authorship：Lead author   Language：Japanese   Publishing type：Research paper (scientific journal)  

DOI： https://doi.org/10.5794/jjoms.67.410

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.3390/cancers12113167

Scopus

PubMed

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1038/s41374-020-0462-z

Scopus

PubMed

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Human Pathology: Case Reports  

DOI： 10.1016/j.ehpc.2016.08.006

Scopus

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.18632/oncotarget.7529

PubMed

Language：English   Publishing type：Research paper (scientific journal)  

DOI： https://doi.org/10.3390/onco3010005

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.3389/fpubh.2022.881303.

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/ger.12581

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Materials Science and Engineering C  

DOI： 10.1016/j.msec.2021.111942

Scopus

PubMed

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Oncotarget  

The Purkinje cell protein 4/peptide 19 (PCP4/PEP19) is a novel breast cancer cell expressing peptide, originally found in the neural cells as an anti-apoptotic factor, could inhibit cell apoptosis and enhance cell migration and invasion in human breast cancer cell lines. The expression of PCP4/PEP19 is induced by estrogens in estrogen receptor-positive (ER(+)) MCF-7 cells but also highly expressed in ER(-) SK-BR-3 cells. In this study, we investigated the effects of PCP4/PEP19 on aromatase gene expression in MCF-7 and SK-BR-3 human breast cancer cells. In SK-BR-3 cells but not in MCF-7 cells, PCP4/PEP19 knockdown by siRNA silencing decreased the aromatase expression in gene transcriptional level. When PCP4/PEP19 was overexpressed by CMV promoter-driven PCP4/PEP19 expressing plasmid transfection, aromatase gene transcription increased in SK-BR-3 cells. This aromatase gene transcription is mainly mediated through promoter region PI.1, which is usually active in the placental tissue but not in the breast cancer tissue. These results indicate a new function of PCP4/PEP19 that would enhance aromatase gene upregulation to supply estrogens in heterogeneous cancer microenvironment.

DOI： 10.18632/oncotarget.25651,

Scopus

PubMed

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Histology and Histopathology  

In mucoepidermoid carcinoma (MEC), the most common salivary gland carcinoma, there is a lack of novel prognostic markers, but post-operative early recurrence strongly affects the clinical course and a poor outcome. It is critical to predict which MEC patients are prone to develop recurrence/metastases. Mucins play pivotal roles in influencing cancer biology, thus affecting cell differentiation, adhesion, carcinoma invasion, aggressiveness and/or metastatic potential. Our aim is to elucidate the significance of expression profiles for mucins, particularly MUC4 and MUC6, and their correlations with various clinicopathological features and recurrence in salivary gland MECs. We performed immunohistochemical analyses on patients with surgically resected primary MEC using antibodies against mucin core proteins MUC4/8G7 and MUC6/CLH5 in 73 paraffin-embedded samples. Recurrence was noted in 15 of 73 (20.5%) patients. MUC4 or MUC6 expression was considered to be negative when <30% or 0% of the MEC cells showed positive staining, respectively. MUC4- and/or MUC6-negative expression respectively and variably showed a significant relationship to pathological tumor high-grade, the presence of lymphovascular invasion, lymph node metastasis and/or tumor-related death. In addition, MUC4 showed significantly negative co-expression with MUC6. Kaplan-Meier analyses revealed that not only single MUC4/6-negative expression but also the combination of both predicted significantly shorter disease-free and disease-specific survivals in MECs, especially within the first two years postoperatively. Therefore, each mucin plays a pivotal role in the pathogenesis of MEC progression. The detection of MUC4 and/or MUC6 might be a powerful parameter in the clinical management of MECs in the early postsurgical phase.

DOI： 10.14670/HH-11-913

Scopus

PubMed

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Patient Safety in Surgery  

Background: The prediction of postoperative complications is important for oral and maxillofacial surgeons. We herein aimed to evaluate the efficacy of the Estimation of Physiologic Ability and Surgical Stress (E-PASS) and Acute Physiology, Age, and Chronic Health Evaluation (APACHE) II scoring systems to predict postoperative complications in patients undergoing oral and maxillofacial surgery. Methods: Thirty patients (22 males, 8 females; mean age: 65.1 +/- 12.9 years) who underwent major oral surgeries and stayed in the intensive care unit for postoperative management were enrolled in this study. Postoperative complications were discriminated according to the necessity of the therapeutic intervention by the Medical Department, i.e. according to the Clavien-Dingo classification. E-PASS and APACHE II scores as well as laboratory test values were compared between patients with/without postoperative complications. Results: Postoperative complications were developed in seven patients. The comprehensive risk score (CRS: 1.13 +/- 0.24) and APACHE II score (13.0 +/- 2.58) were significantly higher in patients with postoperative complications than in those without ones (p < 0.01, p < 0.05, respectively). The CRS showed an appropriate discriminatory power for predicting postoperative complications (area under the curve: 0.814). Furthermore, a correlation was detected between APACHE II scores and postoperative data until C-reactive protein levels decreased to < 1.0 mg/L (r = 0.43, p < 0.05). Conclusion: The E-PASS and APACHE II scoring systems were both shown to be useful to predict postoperative complications after oral and maxillofacial surgery.

DOI： 10.1186/s13037-018-0152-6,

Scopus

PubMed

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology  

OBJECTIVE: The purpose of the present study was to elucidate the anatomic characteristics of the maxillary premolars for the planning of dental treatment using cone beam computed tomography (CBCT). STUDY DESIGN: CBCT images were obtained for 150 maxillary premolars in 68 patients. The internal angle formed by the long axis of the maxillary premolars and the long axis of the alveolar bone was evaluated on the cross-sectional images. The vertical relationships between the maxillary premolars and the maxillary sinus were classified into 5 categories. The bone width and internal angle were compared among the images classified into the 5 categories. RESULTS: The internal angle was 25.5 +/- 6.9 degrees at the maxillary first premolars. The incidence of Type I in the maxillary first premolars was 46.7%. In the maxillary second premolars, the incidence of Type I (14.7%) was significantly lower than the total incidence of Types II, III, IV, and V (85.3%). Type I had the significantly largest internal angle (28.0 +/- 7.7 degrees ) among all types for the maxillary first premolars. CONCLUSION: When considering dental treatment in the maxillary premolars, one should observe the inclination of the maxillary premolars to the alveolar bone as well as the position of the inferior wall of the maxillary sinus.

DOI： 10.1016/j.oooo.2017.01.007

Scopus

PubMed

Publisher：Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology  

DOI： 10.1016/j.ajoms.2016.12.007

Scopus

Publisher：エルゼビア・ジャパン(株)  

口腔扁平上皮癌における術前の頸部リンパ節転移診断の精度を高めるため、CT、MRI、超音波、18F-FDG PET画像検査の結果を統合利用するチャート式診断基準システムを開発し、その臨床有用性について検討した。当院で手術を施行した口腔扁平上皮癌患者106名を組み入れ、治療時期に応じて、I群(2005年10月〜2008年8月、45名)、II群(2008年9月〜2010年3月、29名)、III群(2010年4月〜2012年3月、32名)、に分類した。頸部リンパ節転移の診断においては、I群では上述の各画像診断法を統合した判定はせず、個別に利用していた。II群、III群では各画像診断法の所見を統合した診断基準が適用されており、II群ではCT/MRIと超音波検査の両者ともに陰性の場合に転移陰性、III群ではII群の基準に加えPET/CTのmaximum standardized uptake value(SUVmax)が3.2未満の場合に転移陰性とそれぞれ診断していた。cN0と診断されていたのは67例で、50例では経過観察が適用されそのうち12例(24%)では原発巣の再発を見ずに頸部リンパ節転移を発症した。術後転移率はI、II、III群でそれぞれ33、24、13%と、診断基準システムが新しいほど改善したが、陽性的中率は50、40、33%と悪化していた。

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology  

OBJECTIVE: Various types of wound-healing dressings have been used to assist in the healing of surgical wounds. We analyzed the wound-healing process in an animal model using different existing wound dressings. STUDY DESIGN: Full-thickness defects were created using a biopsy punch on the backs of 7-week-old rats. The wounded areas were covered with NEOVEIL (polyglycolic acid [PGA]) or TERUDERMIS (collagen sponge [CS]) affixed using a rat jacket. The wound area, neo-epithelium length, and alpha-smooth muscle actin (alpha-SMA) expression were evaluated and compared among the control, PGA, and CS groups. RESULTS: The wound areas in the control group on days 4 and 7 were significantly smaller than those in the PGA and CS groups. The expression of alpha-SMA in granulation tissue peaked on day 4 for all groups. The expression of alpha-SMA in the control group on days 4 and 7 after injury was greater than in the PGA and CS groups. However, there was no significant difference in the expression of alpha-SMA between the PGA and CS groups. CONCLUSIONS: In this study, PGA and CS suppressed wound contracture and reduced expression of alpha-SMA in wound areas. However, PGA and CS did not affect the neo-epithelium length at the wound site.

DOI： 10.1016/j.oooo.2016.10.023

Scopus

PubMed

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

The PCP4/PEP19 is a calmodulin-binding anti-apoptotic peptide in neural cells but its potential role in human cancer has largely been unknown. We investigated the expression of PCP4/PEP19 in human breast cancer cell lines MCF-7, SK-BR-3, and MDA-MB-231 cells, and found that estrogen receptor (ER)-positive MCF-7 and ER-negative SK-BR-3 cells expressed PCP4/PEP19. In the MCF-7 cells, cell proliferation was estrogen-dependent, and PCP4/PEP19 expression was induced by estrogen. In both cell lines, PCP4/PEP19 knockdown induced apoptosis and slightly decreased Akt phosphorylation. Knockdown of calcium/calmodulin-dependent protein kinase kinase 1 (CaMKK1), resulting in decreased phospho-Akt(Thr308), enhanced apoptosis in SK-BR-3 but not in MCF-7 cells. CaMKK2 knockdown moderately decreased phospho-Akt(Thr308) and increased apoptosis in MCF-7 cells but not in SK-BR-3 cells. These data indicated that PCP4/PEP19 regulates apoptosis but exact mechanism is still unknown. PCP4/PEP19 can therefore potentially serve as independent oncotarget for therapy of PCP4/PEP19-positive breast cancers irrespective of ER expression.

DOI： 10.18632/oncotarget.2161

PubMed

Event date： 2023.1 - 2023.2

Language：Japanese   Presentation type：Poster presentation  

Event date： 2022.11

Language：Japanese   Presentation type：Poster presentation  

Event date： 2022.5

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2022.5

Language：Japanese   Presentation type：Oral presentation (general)  

Event date： 2022.2

Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2022.2 - 2022.3

Language：Japanese   Presentation type：Symposium, workshop panel (nominated)  

Venue：web  

Event date： 2022.2 - 2022.3

Language：Japanese   Presentation type：Poster presentation  

Venue：web  

Event date： 2022.2 - 2022.3

Language：Japanese   Presentation type：Poster presentation  

Venue：web  

Event date： 2021.12

Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2021.11

Language：Japanese   Presentation type：Oral presentation (general)  

Event date： 2021.11

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：千葉  

Event date： 2021.11

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2021.10

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2021.9

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2021.8

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2021.8

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2021.7

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2021.4

Language：English   Presentation type：Oral presentation (general)  

Event date： 2020.5

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2020.3

Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2020.2

Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2020.1

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2019.11

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2019.10

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2019.10

Event date： 2019.10

Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2019.7

Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2019.7

Language：English   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2019.7

Language：English   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2019.6

Event date： 2019.6

Event date： 2019.5

Event date： 2019.3

Event date： 2019.1

Event date： 2018.12

Event date： 2018.11

Event date： 2018.11

Event date： 2018.11

Language：English   Presentation type：Oral presentation (general)  

Venue：Taipei  

Event date： 2018.11

Event date： 2018.11

Language：Japanese  

Event date： 2018.10

Event date： 2018.10

Event date： 2018.7

Language：Japanese  

Event date： 2018.6

Event date： 2018.2

Event date： 2018.2

Event date： 2018.1

Language：Japanese  

Event date： 2017.12

Event date： 2017.11

Event date： 2017.10

Event date： 2017.7

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2017.6

Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2017.5

Event date： 2017.4

Language：Japanese  

Event date： 2017.3

Language：English  

Event date： 2016.10

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2016.9

Language：Japanese  

Event date： 2016.7

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2016.7

Language：Japanese  

Event date： 2016.3

Language：Japanese  

Event date： 2016.2

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Venue：鹿児島市  

Event date： 2016.1

Event date： 2015.11

Language：Japanese   Presentation type：Oral presentation (general)  

Event date： 2015.7

Language：Japanese  

Event date： 2015.6

Event date： 2015.5

Language：Japanese  

Event date： 2015.2

Language：Japanese  

Event date： 2014.12

Language：Japanese  

Event date： 2014.9

Language：Japanese  

Event date： 2014.8

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Event date： 2014.1

Language：Japanese  

Event date： 2014.1

Language：Japanese  

Language：Japanese   Presentation type：Oral presentation (general)  

Language：Japanese   Presentation type：Oral presentation (general)  

Language：Japanese   Presentation type：Oral presentation (general)  

Language：Japanese   Presentation type：Oral presentation (general)  

Language：Japanese   Presentation type：Oral presentation (general)  

Language：Japanese   Presentation type：Oral presentation (general)  

Language：Japanese   Presentation type：Oral presentation (general)  

Language：Japanese   Presentation type：Oral presentation (general)